Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Can the New BA.2.75 Sub-variant Lead To One More COVID-19 Wave?

Author(s): Suman Kumar Ray and Sukhes Mukherjee*

Volume 23, Issue 4, 2023

Published on: 31 March, 2023

Article ID: e020323214247 Pages: 4

DOI: 10.2174/1871526523666230302103609

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

The highly transmissible variation of COVID-19 has a new sub-variant known as a variant BA.2.75, which was initially discovered in India and is now found in at least 10 more countries. The World Health Organization (WHO) officials said that the new variant is actively being monitored. It has yet to be determined if the new variation is more clinically severe than its predecessors. It is known that the Omicron strain sub-variants are responsible for this rise in the worldwide COVID tally. It is too early to know if this sub-variant exhibits additional immune evasion characteristics, or is more clinically severe.

The extremely contagious BA.2.75 sub-variant of Omicron has been documented in India, but there is no evidence yet that it has increased disease severity or dissemination. Many of the BA.2 lineage's sublineages form a unique collection of mutations as it evolves. A related branch of the BA.2 lineage is B.2.75. The size of genomic sequencing must be increased and maintained for the early detection of the variant strains of SARS-CoV-2. BA.2.75 is the second generation of BA.2 variations and has a high transmissibility level.

Keywords: COVID-19, BA.2.75 variant, transmissibility, WHO, second-generation of BA.2 variations, mutations.

Graphical Abstract

[1]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3): 105924.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[2]
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19(3): 141-54.
[http://dx.doi.org/10.1038/s41579-020-00459-7] [PMID: 33024307]
[3]
Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J 2020; 43(4): 328-33.
[http://dx.doi.org/10.1016/j.bj.2020.04.007] [PMID: 32387617]
[4]
Al-Qahtani AA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi J Biol Sci 2020; 27(10): 2531-8.
[http://dx.doi.org/10.1016/j.sjbs.2020.04.033] [PMID: 32336927]
[5]
Mukherjee S, Ray SK. Third Wave of the COVID-19 pandemic: Prominence of initial public health interference. Infect Disord Drug Targets 2022; 22(4): e080222200919.
[http://dx.doi.org/10.2174/1871526522666220208115101] [PMID: 35135456]
[6]
Mukherjee S, Ray SK. The emergence of Omicron SARS-CoV-2 variant (B.1.1.529) - the latest episode in the COVID-19 pandemic with a global riposte. Infect Disord Drug Targets 2022; 22(7): e220422203941.
[http://dx.doi.org/10.2174/1871526522666220422110415] [PMID: 35466885]
[7]
Krammer F. SARS-CoV-2 vaccines in development. Nature 2020; 586(7830): 516-27.
[http://dx.doi.org/10.1038/s41586-020-2798-3] [PMID: 32967006]
[8]
Mukherjee S, Ray SK. The newfangled upsurge of double mutant SARS-CoV-2 virus in 2021-current scenario and inspecting ahead. Recent Adv Anti-Infect Drug Dis 2021; 16(3): 175-8.
[http://dx.doi.org/10.2174/2772434416666211124150255] [PMID: 34819015]
[9]
Ssentongo P, Ssentongo AE, Voleti N, et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: A systematic review and meta-analysis. BMC Infect Dis 2022; 22(1): 439.
[http://dx.doi.org/10.1186/s12879-022-07418-y] [PMID: 35525973]
[10]
Monto AS. The future of SARS-CoV-2 vaccination-lessons from influenza. N Engl J Med 2021; 385(20): 1825-7.
[http://dx.doi.org/10.1056/NEJMp2113403] [PMID: 34739199]
[11]
Could the New BA.2.75 Sub-Variant Lead to Another COVID-19 Wave in India? 2022. Available from: https://science.thewire.in/the-sciences/ba-2-75-sub-variant-new-covid-19-wave/ (Accessed on: December 06, 2022).
[12]
Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): High potential to becoming the next dominating variant. arXiv:220205031v1 2022.
[http://dx.doi.org/10.21203/rs.3.rs-1362445/v1]
[13]
Tiecco G, Storti S, Arsuffi S, et al. Omicron BA.2 lineage, the “Stealth” variant: Is it truly a silent epidemic? A literature review. Int J Mol Sci 2022; 23(13): 7315.
[http://dx.doi.org/10.3390/ijms23137315] [PMID: 35806320]
[14]
Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 2022; 185(14): 2422-2433.e13.
[http://dx.doi.org/10.1016/j.cell.2022.06.005] [PMID: 35772405]
[15]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[16]
Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. EXCLI J 2020; 19: 410-7.
[PMID: 32210742]
[17]
Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: Implications for the design of spike-based vaccine immunogens. Front Immunol 2020; 11: 576622.
[http://dx.doi.org/10.3389/fimmu.2020.576622] [PMID: 33117378]
[18]
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021; 12: 698169.
[http://dx.doi.org/10.3389/fmicb.2021.698169] [PMID: 34248921]
[19]
Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020; 24(1): 422.
[http://dx.doi.org/10.1186/s13054-020-03120-0] [PMID: 32660650]
[20]
Xie Y, Karki CB, Du D, et al. Spike proteins of SARS-CoV and SARS-CoV-2 utilize different mechanisms to bind with human ACE2. Front Mol Biosci 2020; 7: 591873.
[http://dx.doi.org/10.3389/fmolb.2020.591873] [PMID: 33363207]
[21]
Mengist HM, Kombe Kombe JA, Jin T. Immune evasion by the highly mutated SARS-CoV-2 omicron variant. Infect Drug Resist 2022; 15: 4013-27.
[http://dx.doi.org/10.2147/IDR.S366437]
[22]
Shaheen N, Mohamed A, Soliman Y, et al. Could the new BA.2.75 sub-variant lead to another COVID-19 wave in the world? - Correspondence. Int J Surg 2022; 105: 106861.
[http://dx.doi.org/10.1016/j.ijsu.2022.106861]
[23]
Xia S, Wang L, Zhu Y, Lu L, Jiang S. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct Target Ther 2022; 7(1): 241.
[http://dx.doi.org/10.1038/s41392-022-01105-9]
[24]
Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of coronavirus (COVID-19) [Updated 2022 Oct 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK554776/
[25]
Shaheen N, Mohamed A, Attalla A, et al. Could the new BA.2.75 sub-variant cause the emergence of a global epidemic of COVID-19? A scoping review. Infect Drug Resist 2022; 15: 6317-30.
[http://dx.doi.org/10.2147/IDR.S387551]
[26]
Hachmann NP, Miller J, Ventura JD, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022; 387(1): 86-8.
[27]
Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science 2022; 377(6603): eabq1841.
[28]
Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022; 608(7923): 593-602.
[http://dx.doi.org/10.1038/s41586-022-04980-y] [PMID: 35714668]
[29]
Windsor IW, Tong P, Lavidor O, et al. Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1. Sci Immunol 2022; 7(74): eabo3425.
[http://dx.doi.org/10.1126/sciimmunol.abo3425] [PMID: 35536154]
[30]
van Gils MJ, Lavell A, van der Straten K, et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med 2022; 19(5): e1003991.
[http://dx.doi.org/10.1371/journal.pmed.1003991] [PMID: 35580156]
[31]
Mukherjee S, Ray SK. A new wave of COVID-19 in 2021 with unique genetic characters - present global scenario and beholding onwards. Infect Disord Drug Targets 2022; 22(6): 29-40.
[PMID: 35366784]
[32]
Mukherjee S, Ray SK. From bench side to bed-travelling on a road to get a safe and effective vaccine against COVID-19, day to save the life. Recent Pat Biotechnol 2022; 16(1): 2-5.
[http://dx.doi.org/10.2174/1872208315666211209094457] [PMID: 34886784]
[33]
Chemaitelly H, Tang P, Coyle P, et al. National Study Group for COVID-19 Epidemiology. Protection against reinfection with the Omicron BA.2.75 subvariant. N Engl J Med 2023; 388(7): 665-7.
[http://dx.doi.org/10.1056/NEJMc2214114]

Rights & Permissions Print Cite
Article Metrics
11
4
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy